Shuqing Wei

Taiyuan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids.

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids.

Journal: Frontiers in oncology

Published: November 10, 2025

redictive value of LCP1 and ADPGK for immune-related adverse events across multiple cancer types in patients receiving immunotherapy-based regimens.

redictive value of LCP1 and ADPGK for immune-related adverse events across multiple cancer types in patients receiving immunotherapy-based regimens.

Journal: Acta biochimica et biophysica Sinica

Published: November 03, 2025

RUNX1 Directly Activates WNT2 to Orchestrate Tumor-Associated Macrophage Reprogramming in Colorectal Cancer.

RUNX1 Directly Activates WNT2 to Orchestrate Tumor-Associated Macrophage Reprogramming in Colorectal Cancer.

Journal: Molecular carcinogenesis

Published: October 13, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Journal: BMC medicine

Published: July 30, 2025

Case Report: Stable disease achieved in a patient with metastatic castration-resistant prostate cancer following personalized treatment.

Case Report: Stable disease achieved in a patient with metastatic castration-resistant prostate cancer following personalized treatment.

Journal: Frontiers in oncology

Published: July 25, 2025

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2025

A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma.

A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma.

Journal: Frontiers in cell and developmental biology

Published: March 20, 2025

Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

Journal: International immunopharmacology

Published: November 23, 2024

Combination of tumor organoids with advanced technologies: A powerful platform for tumor evolution and treatment response (Review).

Combination of tumor organoids with advanced technologies: A powerful platform for tumor evolution and treatment response (Review).

Journal: Molecular medicine reports

Published: October 16, 2024

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.

Journal: Gynecologic oncology

Published: June 24, 2024

Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma.

Case report: Patient-derived organoids promoting personalized treatment in invasive urothelial carcinoma.

Journal: Frontiers in oncology

Published: April 28, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026